Venture capital company Dynamk Capital has invested in FloDesign Sonics citing its acoustic wave separation technology’s application in the growing CAR T cell sector.
TxCell SA has developed the production process for it range of CAR-Treg based therapies and is preparing to transfer it to its CMO ahead of first-in-human trials.
Eli Lilly has projected an increased spend across its biomanufacturing network next year to support bulk production and fill/finish of monoclonal antibodies.
CAR T developers must be involved throughout the entire supply chain says Kite Pharma, which depends on accreditation and training programmes across its network of Yescarta administration clinics.
The EMA has accepted to review Mylan’s trastuzumab and pegfilgrastim biosimilars amid remediation efforts at biomanufacturing partner Biocon’s fill and finish plant in India.
Pall Corporation has launched a monoclonal antibody clarification platform without centrifugation or process additives to support cell cultures of up to 2,000L.
Antibody-drug conjugate (ADC) developers are at risk of aggregation issues caused by the hydrophobic nature of next-generation linker-payloads, says ADC Bio.
